Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. The company’s pharmaceutical products are sold in over 100 countries. The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.
Financial Results:
Strides Pharma Science Ltd reported Revenues for Q3FY24 of ₹1,038.00 Crores up from ₹865.00 Crore year on year, a rise of 20.0%.
Total Expenses for Q3FY24 of ₹1,026.00 Crores up from ₹1,010.00 Crores year on year, a rise of 1.58%.
Consolidated Net Profit of ₹54.00 Crores from -₹82.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹5.41, from -₹8.86 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.